Nishit B Modi

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4842926/publications.pdf

Version: 2024-02-01

59	2,021	304701	243610
papers	citations	22 h-index	44 g-index

60	60	60	1414
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Development of a New Once-a-Day Formulation of Methylphenidate for the Treatment of Attention-deficit/Hyperactivity Disorder. Archives of General Psychiatry, 2003, 60, 204.	12.3	228
2	TNK-Tissue Plasminogen Activator in Acute Myocardial Infarction. Circulation, 1997, 95, 351-356.	1.6	209
3	Pharmacokinetics and Pharmacodynamics of Tenecteplase in Fibrinolytic Therapy of Acute Myocardial Infarction. Clinical Pharmacokinetics, 2002, 41, 1229-1245.	3.5	188
4	Orally Active Fibrinogen Receptor Antagonists. 2. Amidoximes as Prodrugs of Amidines. Journal of Medicinal Chemistry, 1996, 39, 3139-3147.	6.4	117
5	Single- and Multiple-Dose Pharmacokinetics of Dapoxetine Hydrochloride, a Novel Agent for the Treatment of Premature Ejaculation. Journal of Clinical Pharmacology, 2006, 46, 301-309.	2.0	117
6	Single- and Multiple-Dose Pharmacokinetics of an Oral Once-a-Day Osmotic Controlled-Release OROSÂ® (methylphenidate HC1) Formulation. Journal of Clinical Pharmacology, 2000, 40, 379-388.	2.0	97
7	Crossover comparison of IPX066 and a standard levodopa formulation in advanced Parkinson's disease. Movement Disorders, 2011, 26, 2246-2252.	3.9	90
8	Pharmacokinetics of a Slower Clearing Tissue Plasminogen Activator Variant, TNK-tPA, in Patients with Acute Myocardial Infarction. Thrombosis and Haemostasis, 1998, 79, 134-139.	3.4	72
9	Comparison of the pharmacokinetics of an oral extendedâ€release capsule formulation of carbidopaâ€levodopa (IPX066) with immediateâ€release carbidopaâ€levodopa (Sinemet^{Â®}), sustainedâ€release carbidopaâ€levodopa (Sinemet^{Â®} CR), and carbidopaâ€levodopaâ€entacapone (Stalevo^{Â®}). Journal of Clinical Pharmacology, 2015, 55, 995-1003.	2.0	65
10	Pharmacokinetics of Methylphenidate in Preschoolers with Attention-Deficit/Hyperactivity Disorder. Journal of Child and Adolescent Psychopharmacology, 2007, 17, 153-164.	1.3	58
11	Application of Neural Networks to Pharmacodynamics. Journal of Pharmaceutical Sciences, 1993, 82, 918-926.	3.3	52
12	Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharmaceutics and Drug Disposition, 2000, 21, 23-31.	1.9	48
13	Pharmacokinetics of a Transdermal Testosterone System in Men with End Stage Renal Disease Receiving Maintenance Hemodialysis and Healthy Hypogonadal Men1. Journal of Clinical Endocrinology and Metabolism, 2001, 86, 2437-2445.	3.6	47
14	Population analyses of sustained-release verapamil in patients: Effects of sex, race, and smoking. Clinical Pharmacology and Therapeutics, 2003, 73, 31-40.	4.7	46
15	Application ofin vitro-in vivo correlations (IVIVC) in setting formulation release specifications. Biopharmaceutics and Drug Disposition, 2000, 21, 321-326.	1.9	44
16	Pharmacokinetics and Pharmacodynamics of Tenecteplase: Results from a Phase II Study in Patients with Acute Myocardial Infarction. Journal of Clinical Pharmacology, 2000, 40, 508-515.	2.0	42
17	Pharmacokinetics of Dapoxetine, a New Treatment for Premature Ejaculation: Impact of Age and Effects of a High-Fat Meal. Journal of Clinical Pharmacology, 2006, 46, 1023-1029.	2.0	42
18	Neural networks in pharmacodynamic modeling. Is current modeling practice of complex kinetic systems at a dead end?. Journal of Pharmacokinetics and Pharmacodynamics, 1992, 20, 397-412.	0.6	40

#	Article	IF	Citations
19	Pharmacokinetics of RytaryÂ®, An Extended-Release Capsule Formulation of Carbidopaâ€“Levodopa. Clinical Pharmacokinetics, 2017, 56, 999-1014.	3.5	33
20	Pharmacokinetics, Pharmacodynamics and Tolerability of a Potent, Non-peptidic, GP IIb/IIIa Receptor Antagonist following Multiple Oral Administrations of a Prodrug Form. Thrombosis and Haemostasis, 1998, 79, 169-176.	3.4	32
21	Population Pharmacodynamics of IPX066: An Oral Extendedâ€Release Capsule Formulation of Carbidopaâ€“Levodopa, and Immediateâ€Release Carbidopaâ€“Levodopa in Patients With Advanced Parkinson's Disease. Journal of Clinical Pharmacology, 2013, 53, 523-531.	2.0	23
22	Conversion to IPX066 from Standard Levodopa Formulations in Advanced Parkinsonâ€™s Disease: Experience inÂClinicalÂTrials. Journal of Parkinson's Disease, 2015, 5, 837-845.	2.8	22
23	Pharmacokinetics and pharmacodynamics of recombinant proteins and peptides. Journal of Controlled Release, 1994, 29, 269-281.	9.9	19
24	Pharmacokinetics and Pharmacodynamic, Pharmacokinetic, Pharmacodynamic, and Electrocardiographic Effects of Dapoxetine and Moxifloxacin Compared With Placebo in Healthy Adult Male Subjects. Journal of Clinical Pharmacology, 2009, 49, 634-642.	2.0	19
25	Clinical Pharmacokinetics of IPX066. Clinical Neuropharmacology, 2016, 39, 10-17.	0.7	19
26	A System Approach to Pharmacodynamics. Input-Effect Control System Analysis of Central Nervous System Effect of Alfentanil. Journal of Pharmaceutical Sciences, 1993, 82, 266-272.	3.3	17
27	Pharmacokinetics and Pharmacodynamics of TP-9201, a GPIIbIIIa Antagonist, in Rats and Dogs. Journal of Cardiovascular Pharmacology, 1995, 25, 888-897.	1.9	17
28	Pharmacokinetics and safety of bevacizumab administered in combination with cisplatin and paclitaxel in cynomolgus monkeys. Cancer Chemotherapy and Pharmacology, 2008, 61, 607-614.	2.3	16
29	Dapoxetine Has No Pharmacokinetic or Cognitive Interactions With Ethanol in Healthy Male Volunteers. Journal of Clinical Pharmacology, 2007, 47, 315-322.	2.0	15
30	Pharmacodynamic System Analysis of the Biophase Level Predictor and the Transduction Function. Journal of Pharmaceutical Sciences, 1992, 81, 925-934.	3.3	14
31	Onset and duration of effect of extended-release carbidopa-levodopa in advanced Parkinson’s disease. Neuropsychiatric Disease and Treatment, 2018, Volume 14, 839-845.	2.2	14
32	An Algorithm for Constrained Deconvolution Based on Reparameterization. Journal of Pharmaceutical Sciences, 1992, 81, 175-180.	3.3	12
33	Pharmacokinetics and pharmacodynamics of recombinant tissue-type plasminogen activator following intravenous administration in rabbits: a comparison of three dosing regimens. Biopharmaceutics and Drug Disposition, 1998, 19, 31-38.	1.9	11
34	Pharmacokinetics, metabolism, and excretion of nefopam, a dual reuptake inhibitor in healthy male volunteers. Xenobiotica, 2016, 46, 1001-1016.	1.1	11
35	Pharmacodynamics, Efficacy, and Safety of IPX203 in Parkinson Disease Patients With Motor Fluctuations. Clinical Neuropharmacology, 2019, 42, 149-156.	0.7	11
36	Single-Dose Pharmacokinetics and Pharmacodynamics of IPX203 in Patients With Advanced Parkinson Disease: A Comparison With Immediate-Release Carbidopa-Levodopa and With Extended-Release Carbidopa-Levodopa Capsules. Clinical Neuropharmacology, 2019, 42, 4-8.	0.7	10

#	Article	IF	Citations
37	Doseâ€Response Analysis of the Effect of Carbidopaâ€Levodopa Extendedâ€Release Capsules (IPX066) in LevodopaâNaive Patients With Parkinson Disease. Journal of Clinical Pharmacology, 2016, 56, 974-982.	2.0	9
38	Determination of Ro 48-3656 in rat plasma by reversed-phase high-performance liquid chromatography. Biomedical Applications, 1997, 704, 231-242.	1.7	8
39	Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered IIb/IIIa Antagonist, in Patients with Acute Coronary Syndrome. Journal of Clinical Pharmacology, 1999, 39, 675-684.	2.0	8
40	Application of a System Analysis Approach to Population Pharmacokinetics and Pharmacodynamics of Nicardipine Hydrochloride in Healthy Males. Journal of Pharmaceutical Sciences, 1993, 82, 705-713.	3.3	7
41	Pharmacokinetics of controlled-release verapamil in healthy volunteers and patients with hypertension or angina. Biopharmaceutics and Drug Disposition, 2002, 23, 17-31.	1.9	7
42	A System Approach to Pharmacodynamics. Plasma Iron Mobilization by Endogenous Erythropoietin in the Sheep Fetus; Evidence of Threshold Response in Spontaneous Hypoxemia. Journal of Pharmaceutical Sciences, 1993, 82, 804-807.	3.3	6
43	Pharmacokinetics and Pharmacodynamics of Warfarin When Coadministered With Pentosan Polysulfate Sodium. Journal of Clinical Pharmacology, 2005, 45, 919-926.	2.0	6
44	Application of Pharmacokinetics and Pharmacodynamics in Product Life Cycle Management. A Case Study with a Carbidopa-Levodopa Extended-Release Formulation. AAPS Journal, 2017, 19, 607-618.	4.4	6
45	Phenobarbital removal characteristics of three brands of activated charcoals: a system analysis approach. Pharmaceutical Research, 1994, 11, 318-323.	3.5	5
46	Pharmacokinetics and Pharmacodynamics of TP-9201, a gpIIbIIIa Antagonist, Administered in Combination with Recombinant Tissue-Type Plasminogen Activator, Heparin, and Aspirin in Beagles. Journal of Cardiovascular Pharmacology, 1996, 27, 105-112.	1.9	5
47	Pharmacokinetics and Pharmacodynamics of Sibrafiban (Ro 48-3657), an Orally Active IIb/IIIa Antagonist, Administered Alone or in Combination with Heparin, Aspirin, and Recombinant Tissue-Type Plasminogen Activator in Beagles. Journal of Cardiovascular Pharmacology, 1998, 32, 397-405.	1.9	5
48	Optimal extravascular dosing intervals. Journal of Pharmacokinetics and Pharmacodynamics, 1991, 19, 405-412.	0.6	4
49	Application of a Variable Direction Hysteresisminimization Approach in Describing the Central Nervous System Pharmacodynamic Effects of Alfentanil in Rabbits. Journal of Pharmaceutical Sciences, 1994, 83, 351-356.	3.3	4
50	Pharmacokinetics and Pharmacodynamics of Sibrafiban, an Orally Administered GP IIb/IIIa Antagonist, following Coadministration of Aspirin and Heparin. Journal of Clinical Pharmacology, 2000, 40, 488-495.	2.0	4
51	Validation of a variable direction hysteresis minimization pharmacodynamic approach: cardiovascular effects of alfentanil. Pharmaceutical Research, 1994, 11, 128-135.	3.5	2
52	Pharmacokinetics and Metabolism in Drug Discovery and Preclinical Development. , 2002, , .		2
53	Dapoxetine and Paroxetine for the Treatment of Premature Ejaculation. Clinical Neuropharmacology, 2007, 30, 315.	0.7	1
54	Recombinant Coagulation Factors and Thrombolytic Agents. , 2013, , 299-320.		1

#	Article	IF	Citations
55	Pharmacokinetics, distribution, metabolism, and excretion of the dual reuptake inhibitor [¹⁴C]-nefopam in rats. Xenobiotica, 2016, 46, 1026-1048.	1.1	1
56	124 Pharmacokinetics and dynamics of longer half-life and PAI-1 resistant tissue plasminogen activator mutants: Slow clearing molecules are not rapidly inhibited. Fibrinolysis and Proteolysis, 1997, 11, 35.	1.1	0
57	Cognitive Effects of Immediate-Release and Extended-Release Oxybutynin in an Elderly Population. Obstetrics and Gynecology, 2006, 107, 4S.	2.4	0
58	Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules: Comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone. Parkinsonism and Related Disorders, 2016, 22, e16.	2.2	0
59	Onset and duration of motor effects with IPX066, levodopa-carbidopa extended-release capsules: comparison with immediate-release levodopa-carbidopa and with levodopa-carbidopa+entacapone. Parkinsonism and Related Disorders, 2016, 22, e93.	2.2	0